Treatment with anti‐OX40L or anti‐TSLP does not alter the frequency of T regulatory cells in allergic asthmatics. Issue 11 (25th August 2015)

• Record Type: Journal Article
• Authors: Baatjes, A. J.; Smith, S. G.; Dua, B.; Watson, R.; Gauvreau, G. M.; O'Byrne, P. M.
• Is Part Of: Allergy. Volume 70:Issue 11(2015:Nov.)
• Page Start: 1505
• Page End: 1508
• Publication Date: 2015-08-25
• Subjects: Allergy -- Periodicals; 616.97
• DOI: 10.1111/all.12708
• Languages: English
• ISSNs: 0105-4538

Abstract

<abstract abstract-type="main" id="all12708-abs-0001"> <title>Abstract</title> <p>OX40‐OX40L interactions and thymic stromal lymphopoietin (TSLP) are important in the induction and maintenance of Th2 responses in allergic disease, whereas T regulatory cells (Treg) have been shown to suppress pro‐inflammatory Th2 responses. Both OX40L and TSLP have been implicated in the negative regulation of Treg. The effect of anti‐asthma therapies on Treg is not well known. Our aim was to assess the effects of two monoclonal antibody therapies (anti‐OX40L and anti‐TSLP) on Treg frequency using a human model of allergic asthma. We hypothesized that the anti‐inflammatory effects of these therapies would result in an increase in circulating Treg (CD4⁺CD25⁺CD127^lowFoxp3⁺ cells) frequency. We measured Treg using flow cytometry, and our results showed that neither allergen challenge nor monoclonal antibody therapy altered circulating Treg frequency. These data highlight the need for assessment of airway Treg and for a more complete understanding of Treg biology so as to develop pharmacologics/biologics that modulate Treg for asthma therapy.</p> </abstract>